Angiola Spinetti
Biographic Data
| ID | 4793285 |
|---|---|
| NAME | Angiola Spinetti |
| GIVEN NAMES | Angiola |
| FAMILY NAME | Spinetti |
| SIGNATURE | SPINETTI A |
| AFFILIATIONS | University of Brescia |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Navigating healthcare pathways
Viral hepatitis is a leading cause of mortality and a global public health challenge that, until recently, has been largely neglected as a health priority. This study describes the prevalence of viral hepatitis B and C in asylum seekers and refugees who participated in screening across three cities in Northern Italy. The analysis highlights significant pitfalls in linkage and retention in care, as well as factors associated with continuing or dis…
Chronic Hepatitis C Cascade of Care in Prisoners—Is There Still Some Work to Do? Analysis of Two Large Penitentiaries in Northern Italy
Penitentiaries have a higher burden of communicable diseases compared to the general population. Prisoners should be tested for hepatitis C virus (HCV) and have direct access to treatment. We analysed the HCV cascade of care in two penitentiaries in Brescia, Northern Italy. At admission, prisoners are offered a voluntary screening for HCV, while patients with known infections are tested with an HCVRNA measurement. We performed an observational re…
DAA Treatment Failure in a HIV/HBV/HCV Co-Infected Patient Carrying a Chimeric HCV Genotype 4/1b
Approved direct antiviral agent (DAA) combinations are associated with high rates of sustained virological response (SVR) and the absence of a detectable hepatitis C viral load 12-24 weeks after treatment discontinuation. However, a low percentage of individuals fail DAA therapy. Here, we report the case of a HIV/HBV/HCV co-infected patient who failed to respond to DAA pangenotypic combination therapy. The sequencing of NS5a, NS5b, NS3 and core r…
No prominent works on this page.
DAA Treatment Failure in a HIV/HBV/HCV Co-Infected Patient Carrying a Chimeric HCV Genotype 4/1b
Approved direct antiviral agent (DAA) combinations are associated with high rates of sustained virological response (SVR) and the absence of a detectable hepatitis C viral load 12-24 weeks after treatment discontinuation. However, a low percentage of individuals fail DAA therapy. Here, we report the case of a HIV/HBV/HCV co-infected patient who failed to respond to DAA pangenotypic combination therapy. The sequencing of NS5a, NS5b, NS3 and core r…
Chronic Hepatitis C Cascade of Care in Prisoners—Is There Still Some Work to Do? Analysis of Two Large Penitentiaries in Northern Italy
Penitentiaries have a higher burden of communicable diseases compared to the general population. Prisoners should be tested for hepatitis C virus (HCV) and have direct access to treatment. We analysed the HCV cascade of care in two penitentiaries in Brescia, Northern Italy. At admission, prisoners are offered a voluntary screening for HCV, while patients with known infections are tested with an HCVRNA measurement. We performed an observational re…
Navigating healthcare pathways
Viral hepatitis is a leading cause of mortality and a global public health challenge that, until recently, has been largely neglected as a health priority. This study describes the prevalence of viral hepatitis B and C in asylum seekers and refugees who participated in screening across three cities in Northern Italy. The analysis highlights significant pitfalls in linkage and retention in care, as well as factors associated with continuing or dis…
Hepatitis B Virus Studies (3 works) · Hepatitis C virus research (3 works) · Medicine (3 works) · Virology (3 works) · Virus (3 works) · Hepatitis C virus (2 works) · Internal Medicine (2 works) · Biology (1 work) · Chronic hepatitis (1 work) · Discontinuation (1 work)